NCT04201431View on ClinicalTrials.gov

Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 24, 2020

Primary Completion Date

July 14, 2022

Study Completion Date

July 14, 2022

Conditions
Malaria, Vivax
Interventions
BIOLOGICAL

PvDBPII/Matrix-M1

50ug PvDBPII in 50ug Matrix M1

Trial Locations (1)

OX3 7LE

CCVTM, University of Oxford, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT04201431 - Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 | Biotech Hunter | Biotech Hunter